MedDataX Logo

To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions

NCT ID: NCT00946465

Last Updated: 2017-03-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-10-31

Study Completion Date

2004-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To demonstrate the relative bioavailability study of Ramipril 10 mg capsules under fasting conditions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Non-Fasting Conditions

NCT00946621

Hypertension
COMPLETED PHASE1

A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions

NCT00864448

Healthy
COMPLETED PHASE1

A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fed Conditions

NCT00864162

Healthy
COMPLETED PHASE1

Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions

NCT00829452

Healthy
COMPLETED PHASE1

Bioavailability Study of Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited Under Fasting Conditions

NCT01164761

Healthy
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Ramipril 10 Capsule (Sandoz)

Group Type EXPERIMENTAL

Ramipril 10 Capsule (Sandoz)

Intervention Type DRUG

2

Altace (Ramipril) 10 Capsule (Aventis Pharmaceutical)

Group Type ACTIVE_COMPARATOR

Altace (Ramipril) 10 Capsule (Aventis Pharmaceutical)

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ramipril 10 Capsule (Sandoz)

Intervention Type DRUG

Altace (Ramipril) 10 Capsule (Aventis Pharmaceutical)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria

* Positive test results for HIV or hepatitis B or C.
* Treatment for drug or alcohol dependence.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sandoz

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sandoz Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Steven Herrmann, M.D., PhD

Role: PRINCIPAL_INVESTIGATOR

Cetero Research, San Antonio

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B043723

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Bioequivalence Study of Ramipril 10 mg Capsules Under Fasting Conditions
NCT00879476 COMPLETED NA
Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions
NCT00828321 COMPLETED PHASE1
A Relative Bioavailability Study of Ramipril 10 mg Capsules Administered Orally as a Sprinkle on Applesauce
NCT00863915 COMPLETED PHASE1
Bioequivalency Study of Ramipril 10 mg Capsules Under Fasting Conditions
NCT00702091 COMPLETED NA
Bioavailability Study of Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited, Under Non-Fasting Conditions
NCT01164774 COMPLETED PHASE1
Ramipril 10 mg Capsule in Healthy Subjects Under Fed Conditions
NCT00829530 COMPLETED PHASE1
Bioequivalence Study of Ramipril 10 mg Capsules Under Fed Conditions
NCT00879788 COMPLETED NA
Bioequivalency Study of Ramipril 10 mg Capsules Under Fed Conditions
NCT00702260 COMPLETED NA
A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Under Fasting Conditions
NCT00870142 COMPLETED PHASE1
A Study Comparing Amounts of Tafamidis In The Blood Without Food
NCT02697864 COMPLETED PHASE1
Bioequivalence Study of Two Formulations of Tablets Ramipril 10 mg in Healthy Volunteers Under Fasting Conditions
NCT05438316 COMPLETED PHASE1
Influence of Food on the Bioavailability of Telmisartan / Ramipril Fixed Dose Combination in Healthy Male and Female Volunteers
NCT02214966 COMPLETED PHASE1
Bioequivalence Study of Amlodipine Tablets Under Fasting Conditions
NCT00775905 COMPLETED NA
Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers
NCT01284621 COMPLETED PHASE1
Amlodipine 10 mg Tablets Under Fasting Conditions
NCT00841542 COMPLETED PHASE1
Ropinirole 0.25 mg Tablets Under Fasting Conditions
NCT00829504 COMPLETED PHASE1
To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg
NCT00946725 COMPLETED PHASE1
Fasting Study of Amlodipine and Benazepril HCl Capsules 10 mg/20 mg to Lotrel® Capsules 10 mg/20 mg
NCT00649519 COMPLETED PHASE1
Comparative Bioavailability Study of Lisinopril Tablets, 10 mg
NCT01375244 COMPLETED PHASE1
A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Tablets Under Fed Conditions
NCT00870571 COMPLETED PHASE1
Bioequivalence Study of Fosinopril 40mg Tablets Under Fasting Conditions
NCT00776334 COMPLETED NA
Bioequivalency Study of Amlodipine Tablets Under Fasting Conditions
NCT00602017 COMPLETED NA
Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fasting Conditions
NCT00834977 COMPLETED PHASE1
Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects
NCT05418348 COMPLETED PHASE1
Omeprazole Delayed Release (DR) Capsules Bioequivalence Study of Dr. Reddys Under Fasting Conditions
NCT01170169 COMPLETED PHASE1